June 18, 2014

New web portal, built in collaboration with GlobalCures, will accelerate the open medical research approach to discover affordable, effective repurposed therapies

Marquette Intellectual Property Review, Volume 18, Issue 1 (2014)

Dr. Bruce Bloom

The current medical solution industry, with amazing scientists and businesspeople working as hard as they can, is not creating treatments and cures for most of the world's diseases. Pharma in 2013 is using a fifty-year-old business model to leverage current knowledge and technology, but that is generating few new treatments, and each treatment increases healthcare costs.  Read More



by Shawn Radcliffe, January 14, 2014

Copy of drugsResearchers are testing existing drugs and compounds as they search for new cancer treatments hidden in plain site.

Blood pressure medications, antidepressants, antipsychotics: these may seem like unlikely cancer fighters, but in the search for effective new treatments, researchers are casting a wider net in hopes of finding existing compounds that improve patients' chances of survival.
In addition to providing alternative treatments, repurposed—or repositioned—drugs, as they are called, can also help researchers understand how a particular disease works or identify new molecular targets that can lead to even more effective drugs.  Read full article here

Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases

Repurposing has the objective of targeting existing drugs and failed, abandoned, or yet-to-be-pursued clinical candidates to new disease areas. The open-source model permits for the sharing of data, resources, compounds, clinical molecules, small libraries, and screening platforms to cost-effectively advance old drugs and/or candidates into clinical re-development. Clearly, at the core of drug-repurposing activities is collaboration, in many cases progressing beyond the open sharing of resources, technology, and intellectual property, to the sharing of facilities and joint program development to foster drug-repurposing human-capacity development. A variety of initiatives under way for drug repurposing, including those targeting rare and neglected diseases, are discussed in this review and provide insight into the stakeholders engaged in drug-repurposing discovery, the models of collaboration used, the intellectual property-management policies crafted, and human capacity developed. Read full article 

FierceBiotech November 2013

FailedDrugsThe true cost of drugs that fail in clinical trials should be measured by far more than the cash poured into the development process. Everyone loses something, whether it be the patients who are waiting for new treatments or the companies losing resources that could have gone back into bolstering R&D.

Some of the investment into these failed or shelved drugs can be recouped by giving them a second and often lower-risk chance in a new indication. This is known as drug repositioning, drug repurposing or drug rescue. It may be carried out by the company that invented the drug, but it’s more commonly pursued these days by smaller, more specialized companies.  

Read more

Rediscovery More for Less

ebr July 2013Dr. Bruce Bloom, July 2013

Conducting medical research for drug rediscovery is a growing challenge, as the amount that is spent on it is minimal. However, there are many advantages with this method that are being overlooked See full article here

Cover Story by Ann Thayer  Volume 90 Issue 40, October 1, 2012

Drug Repurposing Finding new uses for approved drugs and shelved drug candidates is gaining steam as a pharmaceutical development strategy.

This fall, at least three conferences will bring together researchers to discuss how finding new uses for known drug compounds can be a strategy for both clinical development and business growth. A few years ago, no such conferences existed. The attendee lists show that interest is widespread among large pharmaceutical companies, small biotech firms, government agencies, academic groups, and nonprofit organizations alike.

by Lenore Skenazy

November, 2012  on Creators.com

Think of it as Goodwill versus Bloomingdale's — except with medicine.

Today most researchers trying to cure a disease are like designers. They start from scratch in a lab, trying to create something unique and miraculous (and, some hope, lucrative). The odds against them are terrible — for every 10,000 new drugs tested, one actually gets to patients — and the expense is enormous, too; $250 billion in research a year yields maybe 30 new drugs.

Isn't there an alternative?

There is. Call them thrift shop drugs — drugs that were created for some other people with some other disease but that just might work on another ailment, too.

Northbrook Star By Karie Angell Luc July 23, 2012 6:08AM

The longest day of golf has a hole-in-goal of shortening the distance to finding a cure for pediatric brain tumors.

Green Acres Country Club of Northbrook at 916 Dundee Road will host 24 players Monday who will take a swing at 1,400 combined holes of golf to raise $60,000 for pediatric tumor research via the Chicago philanthropicorganization Partnership for Cures.

“There is a personal connection,’ said Steve Goldsher of Northbrook, a print procurement consultant and also Partnership for Cures (volunteer) executive board member.  “Every year (18 year history), we choose a research project to fund with this year being for recurrent pediatric brain tumors.  This year’s research project was inspired by my relationship with the Wehrs and Pete (Weiss) and his family.”

Newsweek Magazine

May 14, 2010 

How the road from promising scientific breakthrough to real-world remedy has become all but a dead end.

By Sharon Begley and Mary Carmichael

From 1996 to 1999, the U.S. food and Drug Administration approved 157 new drugs. In the comparable period a decade later—that is, from 2006 to 2009—the agency approved 74. Not among them were any cures, or even meaningfully effective treatments, for Alzheimer's disease, lung or pancreatic cancer, Parkinson's disease, Huntington's disease, or a host of other afflictions that destroy lives.

Newsweek June 15, 2009

by Sharon Begley

Now that President Obama has almost all of his top science picks in place—from the Department of Energy to the FDA—the lack of an appointee for director of the Nation-al Institutes of Health is standing out like a creationist at an evolution conference. I hope the delay means Obama has grasped the need for, and the difficulty of finding, a powerful director who can get beyond the rhetoric about moving discoveries out of the lab and make it a reality. That hasn't happened yet, six years after a much-ballyhooed NIH "road map" declared such bench-to-bedside research a priority and vowed to reward risk-taking, innovative studies, not the same old incremental research that has produced too few cures.  Read full article

Applied Clinical Trials Online

June 7, 2016

By Bruce Bloom

The case for supporting off-label use or commercialization in drugs for “unsolved” diseases.

There are over 7,000 “unsolved” diseases for which patients have no universally successful treatment. There are also thousands of generic drugs that can be repurposed to help these patients. Built on knowledge from scientific discoveries, anecdotal evidence, and/or bioinformatics, generic drug repurposing research can often lead to quick and affordable development of “new” medical solutions. Once a generic drug repurposing opportunity has been identified, a key issue is whether the clinical trial validation should focus on supporting a path to commercialization or to physician off-label use. The direction of focus depends on the entity supporting the clinical trial development.


Read the full article here

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*


If the link above doesn't work, please email susan@cureswithinreach.org with your Full Name and Email Address to sign up!


Cures Within Reach


All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes.  CWR is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Wednesday the 24th. Copyright 2018 Cures Within Reach.